MicroRNA-30a depresses hepatic stellate cell activation against liver fibrosis through blockade of the TGF-β1/Smad2/3 pathway.

This study explored the mechanism of microRNA (miR)-30a in the activation of hepatic stellate cells (HSCs) to deepen the understanding of the pathogenesis of liver fibrosis. Subsequent to knockdown and ectopic experiments, HSCs were induced with 10 ng/mL transforming growth factor (TGF)-β1 to inspect the role of the miR-30a/TGF-β receptor 1 (TGFBR1) axis in HSC proliferation and activation. qRT-PCR was utilized to examine TGFBR1 mRNA and miR-30a expression and western blot to test TGFBR1, alpha smooth muscle actin (α-SMA), Collagen I and mothers against DPP homolog 2/3 (Smad2/3) protein expression. The fluorescence intensity of α-SMA was measured with immunofluorescence staining. The interaction of TGFBR1 with miR-30a was tested with a dual-luciferase reporter assay. TGF-β1 treated HSCs had upregulated expressions of α-SMA and Collagen I. In addition, downregulated miR-30a, upregulated TGFBR1 and activated TGF-β1/Smad2/3 pathway were found in activated HSCs. Upregulation of miR-30a or downregulation of TGFBR1 suppressed the activation and growth of HSCs. miR-30a repression activated the TGF-β1/Smad2/3 pathway and promoted HSC proliferation and activation, while suppression of TGFBR1 revered these effects. miR-30a was an upstream regulatory factor of TGFBR1. miR-30a blocks the TGF-β1/Smad2/3 pathway to inhibit HSC activation against liver fibrosis by targeting TGFBR1.

[1]  Yongfang Jiang,et al.  Igf2bp2 knockdown improves CCl4-induced liver fibrosis and TGF-β-activated mouse hepatic stellate cells by regulating Tgfbr1. , 2022, International immunopharmacology.

[2]  J. Pi,et al.  circHIPK3 Exacerbates Folic Acid-Induced Renal Tubulointerstitial Fibrosis by Sponging miR-30a , 2022, Frontiers in Physiology.

[3]  Xiaolin Wang,et al.  MicroRNAs as regulators, biomarkers and therapeutic targets in liver diseases , 2020, Gut.

[4]  Jian-hua Zhou,et al.  microRNA‐30a attenuates TGF‐β1–induced activation of pulmonary fibroblast cell by targeting FAP‐α , 2020, Journal of cellular and molecular medicine.

[5]  A. Si,et al.  miR-219 regulates liver cancer stem cell expansion via E-cadherin pathway , 2019, Cell cycle.

[6]  N. Aghaeepour,et al.  iRhom2 inhibits bile duct obstruction–induced liver fibrosis , 2019, Science Signaling.

[7]  Xiaohua Wang,et al.  miR‐193a/b‐3p relieves hepatic fibrosis and restrains proliferation and activation of hepatic stellate cells , 2019, Journal of cellular and molecular medicine.

[8]  Xiaohong Li,et al.  TGF-β receptors: In and beyond TGF-β signaling. , 2018, Cellular signalling.

[9]  C. Bishop,et al.  miR-122 inhibition in a human liver organoid model leads to liver inflammation, necrosis, steatofibrosis and dysregulated insulin signaling , 2018, PloS one.

[10]  Mengtao Zhou,et al.  MicroRNA-30a Suppresses the Activation of Hepatic Stellate Cells by Inhibiting Epithelial-to-Mesenchymal Transition , 2018, Cellular Physiology and Biochemistry.

[11]  Bicheng Chen,et al.  Epigenetically-Regulated MicroRNA-9-5p Suppresses the Activation of Hepatic Stellate Cells via TGFBR1 and TGFBR2 , 2017, Cellular Physiology and Biochemistry.

[12]  He-da Zhang,et al.  miR-30a inhibits the biological function of breast cancer cells by targeting Notch1. , 2017, International journal of molecular medicine.

[13]  Jie Yin,et al.  MicroRNA‐30a ameliorates hepatic fibrosis by inhibiting Beclin1‐mediated autophagy , 2017, Journal of cellular and molecular medicine.

[14]  Jin Ding,et al.  The HLF/IL-6/STAT3 feedforward circuit drives hepatic stellate cell activation to promote liver fibrosis , 2017, Gut.

[15]  Jie Zhang,et al.  ENMD-1068 inhibits liver fibrosis through attenuation of TGF-β1/Smad2/3 signaling in mice , 2017, Scientific Reports.

[16]  J. Iredale,et al.  Regression of Liver Fibrosis , 2017, Seminars in Liver Disease.

[17]  A. Hata,et al.  TGF-β Signaling from Receptors to Smads. , 2016, Cold Spring Harbor perspectives in biology.

[18]  C. Ha,et al.  MicroRNA-378 limits activation of hepatic stellate cells and liver fibrosis by suppressing Gli3 expression , 2016, Nature Communications.

[19]  D. Brenner,et al.  Recent advancement of molecular mechanisms of liver fibrosis , 2015, Journal of hepato-biliary-pancreatic sciences.

[20]  R. Schwabe,et al.  Hepatic inflammation and fibrosis: Functional links and key pathways , 2015, Hepatology.

[21]  S. Friedman,et al.  Pathobiology of liver fibrosis: a translational success story , 2015, Gut.

[22]  J. Ladero.  Noninvasive Evaluation of Liver Fibrosis in Patients with Chronic Hepatitis C , 2011, Hepatitis monthly.

[23]  W. Grady,et al.  TGF-beta receptor levels regulate the specificity of signaling pathway activation and biological effects of TGF-beta. , 2009, Biochimica et biophysica acta.

[24]  Junli Feng,et al.  The quantification of tomato microRNAs response to viral infection by stem-loop real-time RT-PCR. , 2009, Gene.

[25]  R Weiskirchen,et al.  Modern pathogenetic concepts of liver fibrosis suggest stellate cells and TGF-β as major players and therapeutic targets , 2006, Journal of cellular and molecular medicine.

[26]  M. Hudson,et al.  Liver transplantation for chronic liver disease: advances and controversies in an era of organ shortages , 2002, Postgraduate medical journal.